CTLA4 and cancer: The use of immune checkpoint inhibitors (ICIs), such as anti-PD-1, anti-CTLA4, and anti-PD-L1 antibodies, has demonstrated significant benefits in various cancers, including gastric adenocarcinomas (38, 39).